Post-transplant Kaposi's sarcoma

Journal of the American Society of Nephrology

Volumn 8, Issue 1, 1997, Pages 130-137

  Gotti, Eliana ^a   Remuzzi, Giuseppe ^b  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BLEOMYCIN; CHORIONIC GONADOTROPIN; CYCLOSPORIN; DOXORUBICIN; FOSCARNET; RECOMBINANT ALPHA2A INTERFERON; VINBLASTINE; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CELL GROWTH; CLINICAL FEATURE; HERPES VIRUS; HUMAN; IMMUNITY; KAPOSI SARCOMA; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; TRANSPLANTATION;

EID: 0030679782     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/asn.v81130     Document Type: Review

References (98)

1. Safai B, Johnson KG, Myskowski PL, Koziner B, Yang SY, Cunningham-Rundles S, Godbold JH, Dupont B: The natural history of Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med 103: 744-750, 1985
2. Farge D: Kaposi's sarcoma in organ transplant recipients: The collaborative transplantation research group of Ile de France. Eur J Med 2: 339-343, 1993
3. Ziegler JL, Dorfmann R, Eds: Kaposi's Sarcoma: Pathophysiology and Clinical Management, New York, Marcel Decker, 1988
4. Renne R, Zhong W, Herndier B, McGrath M, Abbey N, Kedes D, Ganem D: Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nature Med 2: 342-346, 1996
5. Penn I: sarcomas in organ allograft recipients. Transplantation 60: 1485-1491, 1995
6. Sungur C, Bozdogan O, Sungur A, Oymak O, Yasavul U, Turgan C, Caglar S: Lymphadenopathic aggressive Kaposi's sarcoma in a renal transplant recipient with HLA-DR2 and HLA-DR5 antigens. Nephron 69: 122-123, 1995
7. Stribling J, Weitzner S, Smith GV: Kaposi's sarcoma in renal allograft recipients. Cancer 42: 442-446, 1978
8. Krigel RL, Laubenstein LJ, Muggia FM: Kaposi's sarcoma: A new staging classification. Cancer Treat Rep 67: 531-534, 1983
9. Bronson DM: Immunosuppressive therapy. In: Kaposi's Sarcoma: A Text and Atlas, edited by Gottlieb G, Ackerman AB, Philadelphia, Lea and Febiger, 1988, pp 241-253
10. Penn I: Cancers after cyclosporine therapy. Transplant Proc 20[Suppl 1]: 276-79, 1988
11. Starzl TE: Contribution to organ transplantation to the biology of cancer. In: Accomplishments in Cancer Research, edited by Fortner JG, Rhoads JE, Philadelphia, JB Lippincott Company, 1989, pp 190-201
12. Remuzzi G, Gotti E: The girl with the curl. N Engl J Med 333: 928-31, 1995
13. Hess AD, Donnenberg AD, Engel P, Tutschka PY, Santos GW: Suppressor-cell amplification circuitry in cyclosporine-treated MLR cultures. In: Cyclosporine Biological Activity and Clinical Applications, Vol. I, 1st ed., edited by Kahan BD, Orlando, Grune and Stratton, 1984, pp 127-133
14. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, O'Sullivan EJ, Johnson MR, Heroux AL, Dizikes GJ, Pifarre R, Fisher RI: Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 323: 1723-1728, 1990
15. Doutrelepont J-M, De Pauw L, Gruber SA, et al.: Renal transplantation exposes patients with previous Kaposi's sarcoma to a high risk of recurrence. Transplantation 62: 463-466, 1996
16. Qunibi W, Akhtar M, Sheth K, Ginn HE, Al-Furayh O, Devol EB, Taher S: Kaposi's sarcoma: The most common tumor after renal transplantation in Saudi Arabia. Am J Med 84: 225-32, 1988
17. Sheil AG: Cancer in renal allograft recipients in Australia and New Zealand. Transplant Proc 9: 1133-1136, 1977
18. Margolius LP: Malignancy in Renal Transplant Recipients. [Dissertation for Master of Medicine Degree.] Johannesburg, South Africa, University of the Witwatersrand, 1992
19. Beckstead JH, Wood GS, Fletcher V: Evidence for the origin of Kaposi's sarcoma from lymphatic endothelium. Am J Pathol 119: 294-300, 1985
20. Boshoff C, Schulz TF, Kennedy MM, Graham AK, Fisher C, Thomas A, McGee JO, Weiss RA O'Leary JJ: Kaposi's sarcoma: Associates herpesvirus infects endothelial and spindle cells. Nature Med 1: 1274-1278, 1995
21. Rappersberger K, Wolff K, Stingl G: Kaposi's sarcoma. In: Dermatology in General Medicine, edited by Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF, New York, McGraw Hill, 1993, pp 1244-1256
22. Sturzl M, Brandstetter H, Roth WK: Kaposi's sarcoma: A review of gene expression and ultrastructure of KS spindle cells in vivo. Aids Res Hum Retroviruses 8: 1753-1763, 1992
23. Roth WK, Brandstetter H, Sturzl M: Cellular and molecular features of HIV-associated Kaposi's sarcoma. AIDS 6: 895-913, 1992
24. Nickoloff BJ, Griffiths CE: Factor XIIIa-expressing dermal dendrocytes in AIDS-associated cutaneous Kaposi's sarcomas. Science 243: 1736-1737, 1989
25. Pammer J, Plettenberg A, Weninger W, et al.: CD40 antigen is expressed by endothelial cells and tumor cells in Kaposi's sarcoma. Am J Pathol 148: 1387-1396, 1996
26. Wang F, Gregory C, Sample C, Rowe M, Liebowitz D, Murray R, Rickinson A, Kieff E: Epstein-Barr virus latent membrane protein (LMP 1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA 2 and LMP 1 cooperatively induce CD23. J Virol 64: 2309-2318, 1990
27. Siddiqui A: Hepatitis B virus DNA in Kaposi sarcoma. Proc Natl Acad Sci USA 80: 4861-4864, 1983
28. Beral V, Peterman TA, Berkelman RL, Jaffe HW: Kaposi's sarcoma among persons with AIDS: A sexually transmitted infection? Lancet 335: 123-128, 1990
29. Wang RY, Shih JW, Weiss SH, Grandinetti T, Pierce PF, Lange M, Alter HJ, Wear RY, Davies CL, Mayur RK: Mycoplasma Penetrans infection in male homosexuals with AIDS: High seroprevalence and association with Kaposi's sarcoma. Clin Infect Dis 17: 724-29, 1993
30. Huang YQ, Li JJ, Rush MG, Poiesz BJ, Nicolaides A, Jacobson M, Zhang WG, Coutavas E, Abbott MA, Friedman-Kien AE: HPV-16-related sequences in Kaposi's sarcoma. Lancet 339: 515-518, 1992
31. Biggar RJ, Dunsmore N, Kurman RJ, Shah KV, Kordor J, Cottoni F, Hatzakis A, Gigase PL: Failure to detect human papillomavirus in Kaposi's sarcoma. Lancet 339: 1604-1605, 1992
32. Hirsch MS, Schooley RT, Ho DD, Kaplan JC: Possible viral interactions in the acquired immunodeficiency syndrome. Rev Infect Dis 6: 726-731, 1984
33. Gonczol E, Plotkin SA: Cells infected with human CMV release, a factor(s) that stimulates cell DNA synthesis. J Gen Virol 65: 1833-1837, 1984
34. Drew WL, Conant MA, Miner RC, Huang ES, Ziegler JL, Groundwater JR, Gullett JH, Volberding P, Abrams DI, Mintz L: Cytomegalovirus and Kaposi's sarcoma in young homosexual men. Lancet 2: 125-127, 1982
35. Siegal B, Levinton-Kriss S, Schiffer A, Sayar J, Engelberg I, Vonsover A, Ramon Y, Rubinstein E: Kaposi's sarcoma in immunosuppression: Possibly the results of a dual viral infection. Cancer 65: 429-498, 1990
36. Giraldo G, Beth E, Buonaguro FM: Kaposi's sarcoma: A natural model of interrelationships between viruses, immunologic responses, genetics, and oncogenesis. Antibiot Chemother 32: 1-11, 1984
37. Boldogh I, Beth E, Huang ES, Kyalwazi SK, Giraldo G: Kaposi's sarcoma: IV - Detection of CMV DNA, CMV RNA and CMNA in tumor biopsies. Int J Cancer 28: 469-474, 1981
38. Fenoglio CM, Oster MW, Lo-Gerfo P, Reynolds T, Edelson R, Patterson JA, Madeiros E, McDougall JK: Kaposi's sarcoma following chemotherapy of testicular cancer in a homosexual man: Demonstration of CMV RNA in sarcoma cells. Human Pathol 13: 955-959, 1982
39. Huang EG, Boldogh I, Askar JF, Mar EC: The molecular biology of human CMV and its relationship to various human cancers. In: The Role of Viruses in Human Cancer, edited by Giraldo G, Beth E, Vol. 11, New York, Elsevier Science Publishers, 1984, pp 164-194
40. Epstein MA, Achong BG, Barr YM: Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1: 702-703, 1964
41. Biggar RJ, Henle G, Bocker J, Lennette ET, Fleisher G, Henle W: Primary Epstein-Barr infection in African infants: II - Clinical and serological observations during seroconversion. Int J Cancer 22: 244-250, 1978
42. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS: Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266: 1865-1869, 1994
43. Bovenzi P, Mirandola P, Secchiero P, Strumia R, Cassai E', Di Luca D: Human herpesvirus 6 (variant A) in Kaposi's sarcoma. Lancet 1: 1288-1289, 1993
44. Dupin N, Grandadam M, Calvez V, Gorin I, Aubin JT, Havard S, Lamy F, Leibowitch M, Huraux JM, Escande JP: Herpesvirus-like DNA sequences in patients with Mediterranean Kaposi's sarcoma. Lancet 345: 761-762, 1995
45. Moore PS, Chang Y: Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. N Engl J Med 332: 1181-1185, 1995
46. Boshoff C, Whitby D, Hatziioannou T, Fisher C, Van Der Walt J, Hatzakis A, Weiss R, Schulz T: Kaposi's-sarcoma-associated herpesvirus in HIV-negative Kaposi's sarcoma. Lancet 345: 1043-1044, 1995
47. Huang YQ, Li JJ, Zhang WG, et al: Transcription of human herpesvirus-like agent (HHV-8) in Kaposi's sarcoma. J Clin Invest 97: 2803-2806, 1996
48. Miller G, Rigsby MO, Heston L, et al.: Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection. N Engl J Med 334: 1292-1297, 1996
49. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM: Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 332: 1186-1191, 1995
50. Rady PL, Yen A, Rollefson JL, Orengo I, Bruce S, Hughes TK, Tyring SK: Herpesvirus-like DNA sequences in non-Kaposi's sarcoma skin lesions of transplant patients. Lancet 345: 1339-40, 1995
51. Moore PS, Gao SJ, Dominguez G, Cesarman E, Lungu O, Knowles DM, Garber R, Pellett PE, McGeoch DJ, Chang Y: Primary characterization of a herpes-virus agent associated with Kaposi's sarcoma. J Virol 70: 549-558, 1996
52. Ensoli B, Nakamura S, Salahuddin SZ, Biberfeld P, Larsson L, Beaver B, Wong-Staal F, Gallo RC: AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science 243: 223-226, 1989
53. Corbeil J, Evans LA, Vasak E, Cooper DA, Penny R: Culture and properties of cells derived from Kaposi sarcoma. J Immunol 146: 2972-2976, 1991
54. Miles SA, Rezai AR, Salazar-Gonzales JF, Vander-Meyden M, Stevens RM, Logan DM, Mitsuyasu RT, Taga T, Hirano T, Kishimoto T: AIDS-Kaposi sarcoma- derived cells produce and respond to interleukin 6. Proc Natl Acad Sci USA 87: 4068-4072, 1990
55. Roth WK, Werner S, Shirren CG, Hofschneider PH: Depletion of PDGF from serum inhibits growth of AIDS-related and sporadic Kaposi's sarcoma cells in culture. Oncogene 4: 483-487, 1989
56. Maier JA, Mariotti M, Albini A, Comi P, Prat M, Comogilio PM, Soria MR: Over-expression of hepatocyte growth factor in human Kaposi's sarcoma. Int J Cancer 65: 168-172
57. Ziegler JL, Katongole-Mbidde E, Wabinga H, Dollbaum CM: Absence of sex-hormone receptors in Kaposi's sarcoma. Lancet 345: 925, 1995
58. Whitby D, Howard MR, Tenant-Flowers M, Brink NS, Copas A, Boshoff C, Hatzioannou T, Suggett FE, Aldam DM, Denton AS: Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet 346: 799-802, 1995
59. Monini P, De Lellis L, Fabris M, Rigolin F, Cassai E: Kaposi's sarcoma-associated herpesvirus DNA sequences in prostate tissue and human semen. N Engl J Med 334: 1168-1172, 1996
60. Levine AM: AIDS-related malignancies: The emerging epidemic. J Natl Cancer Inst 85: 1382-1397, 1993
61. Digiovanna JJ, Safai B: Kaposi's sarcoma. Retrospective study of 90 cases with particular emphasis on the familial occurrence, ethnic background and prevalence of other diseases. Am J Med 71: 779-783, 1981
62. Penn I: The changing pattern of posttransplant malignancies. Transplant Proc 23: 1101-1103, 1991
63. Stribling J, Weitzner S, Smith GV: Kaposi's sarcoma in renal allograft recipients. Cancer 42: 442-446, 1978
64. Chanez P, Mourad G, Aubas P, Guillot B, Gadard P, Mion C, Michel FB: Kaposi's sarcoma of the bronchial tree in a renal transplant recipient. Respiration 53: 259-261, 1988
65. Biermann CW, Gasser TC, Rutishauser G, Lloyd DM: Kaposi sarcoma of the bladder following renal transplantation and immunosuppression. Clin Transpl 7: 71-72, 1993
66. Meyers AD, Barker C, Grossman R, Potsic WP, Jafek BW: Kaposi's sarcoma of the oropharynx following renal transplantation. Trans Am Acad Ophthalmol Otolaryngol 82: 560-562, 1976
67. Sheil AG, Disney AP, Mathew TH, Amiss N: De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc 25: 1383-1384, 1993
68. Studniberg HM, Rivers JK, Cooke BE, Barnetson RS: The co-existence of lymphangiosarcoma and Kaposi's sarcoma in a renal transplant recipient. Cancer 68: 2330-2335, 1991
69. Piette WW: The incidence of second malignancies in subsets of Kaposi's sarcoma. J Am Acad Dermatol 16: 855-861, 1987
70. Enzinger FM, Weiss SW: Malignant vascular tumors. In: Soft Tissue Tumors, edited by Enzinger FM, Weiss SW III, St. Louis, Mosby, 1995, pp 641-677
71. Ziegler JL, Dorfman RF: Overview of Kaposi's sarcoma: History, epidemiology, and biomedical features. In: Kaposi's Sarcoma: Pathophysiology and Clinical Management, edited by Ziegler JL, Dorfman RF, New York, Dekker, 1988, p 2
72. Margolius LP, Stein M, Spencer D, Bezwoda WR: Kaposi's sarcoma in renal transplant recipients. S Afr Med J 84: 16-17, 1994
73. Penn I: Cancers following cyclosporine therapy. Transplantation 43: 32-35, 1987
74. Al-Khader AA, Suleiman M, Al-Hasani M, Haleem A: Posttransplant Kaposi's sarcoma: Staging as a guide to therapy and prognosis. Nephron 48: 165, 1988
75. De Wys WD, Curran J, Henle W, Johnson G: Workshop on Kaposi's sarcoma: Meeting report. Cancer Treat Rep 66: 1387-1390, 1982
76. Hardy MA, Goldfarb P, Levine S, Dattner A, Muggia FM, Levitt S, Weinstein E: De novo Kaposi's sarcoma in renal transplantation: Case report and brief review. Cancer 38: 144-148, 1976
77. Richman SP, Vogel CL: Kaposi's sarcoma. In: Current Therapy in Haematology-Oncology-3: Current Therapy Series, edited by Brain MC, Carbone PP, Toronto, BC, Marcel Dekker, 1988, pp 353-355
78. Hengge UR, Brockmeyer NH, Baumann M, Reimann G, Goos M: Liposomal doxorubicin in AIDS-related Kaposi's sarcoma. Lancet 342: 497, 1993
79. Odajnyk C, Muggia FM: Treatment of Kaposi's sarcoma: Overview and analysis by clinical setting. J Clin Oncol 3: 1277-1285, 1985
80. Bogner JR, Kronawitter U, Rolinski B, Truebenbach K, Goebel FD: Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma. J Acquir Immune Defic Syndr 7: 463-468, 1994
81. Flettenberg A, Stoehr A, Dijk U, et al.: Increasing risk for opportunistic infection (CDC IV C1) during chemotherapy in patients with Kaposi's Sarcoma. [Abstract 1557]. IX International Conference on AIDS, Berlin, June 1993
82. Gill PS, Bernstein-Singer N, Espina BM, Rarick M, Magy F, Montgomery T, Berry MS, Levine A: Adriamycin, bleomycin and vincristine chemotherapy with recombinant granulocyte-macrophage colony-stimulating factor in the treatment of AIDS-related Kaposi's sarcoma. AIDS 6: 1477-1481, 1992
83. Rarick MU, Gill PS, Montgomery T, Bernstein-Singer M, Jones B, Levine AM: Treatment of epidemic Kaposi's sarcoma with combination chemotherapy (vincristine and bleomycin) and zidovudine. Ann Oncol 1: 147-149, 1990
84. Groopman JE, Gottlieb MS, Goodman J, Mitsuyasu RT, Conant MA, Prince H, Fahey JL, Derezin M, Weinstein WM, Casavante C: Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with acquired immunodeficiency syndrome. Ann Intern Med 100: 671-676, 1984
85. Stuart-Harris RC, Lauchlan R, Day R: The clinical application of the interferons: A review. NSW Therapeutic assessment group. Med J Aust 156: 869-872, 1982
86. Mitsuyasu RT: Interferon alpha in the treatment of AIDS-related Kaposi' sarcoma. Br J Haematol 79[Suppl 1]: 69-73, 1991
87. Dupuy J, Price M, Lynch G, Bruce S, Schwartz M: Intralesional interferon-alpha and zidovudine in epidemic Kaposi's sarcoma. J Am Acad Dermatol 28: 966-972, 1993
88. Krown SE: Interferon and other biologic agents for the treatment of Kaposi's sarcoma. Hematol Oncol Clin North Am 5: 311-322, 1991
89. Sheil AG: Cancer in organ transplant recipients: part of an induced immune deficiency syndrome. Br Med J Clin Res Ed 288: 659-661, 1984
90. Revillard JP: Immunologic alteration in chronic renal deficiency. Adv Nephrol Necker Hosp 8: 365-382, 1979
91. Stein ME, Lakier R, Spencer D, Dale J, Kuten A, Macpail P, Bezwoda WR: Radiation therapy for non-AIDS associated (classic and endemic African) and epidemic Kaposi's sarcoma. Int J Radiat Oncol Biol Phys 28: 613-619, 1994
92. Geara F, Le Bourgeois JP, Piedbois P, Paulovitch JM, Mazeron JJ: Radiotherapy in the management of cutaneous epidemic Kaposi's sarcoma. Int J Radiat Oncol Biol Phys 21: 1517-1522, 1991
93. Morfeldt L, Torssander J: Long-term remission of Kaposi's sarcoma following Foscarnet treatment in HIV-infected patients. Scand J Infect Dis 26: 749-752, 1994
94. Wagstaff AJ, Bryson HM Foscarnet: A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 48: 199-226, 1994
95. Gallo RHIV: Ten years of research findings and future projects. Tenth International Conference on AIDS, Special Session I, Yokohama, Japan,
96. McNamee D: β-HCG inhibits Kaposi's sarcoma. Lancet 345: 1169, 1995
97. Harris PJ: Treatment of Kaposi's sarcoma and other manifestations of AIDS with human chorionic gonadotropin. Lancet 346: 118-119, 1995
98. Von Overbeck J, Perey L, Iten A, Pechère M, Ruffieux P, Hirschel B: Human chronic gonadotropin for AIDS-related Kaposi's sarcoma. Lancet 346: 642-643, 1995